Covid, Ema: “New and promising therapies are also being studied”

“While we are seeing a lot of progress on Covid vaccines, we also need effective treatments to save the lives of those who get sick after being infected and to bring the pandemic under control. What’s good is that there is an active pipeline. of new and promising therapies for use or in the early stages of Covid in patients who are out of hospitals or for patients already hospitalized with more severe forms “, and” we expect “that the EMA will be able to examine these products” in the year “. “We are having an active dialogue with manufacturers of promising ‘drug’ candidates to ensure they can generate the data they need for rapid approval.” Marco Cavaleri, head of Vaccines and Therapeutic Products for Covid-19 of the European Medicines Agency Ema, took stock of the potential therapies under study for Covid-19, during the periodic press briefing. “Many people are still being treated in hospitals for Covid-19 and there is an urgent need for further treatment options – he stressed – We are strongly supporting the EU Strategy on Covid-19 Therapeutics, accelerating the reviews currently underway on” candidate treatments. “promising” and “maintaining rigorous standards” for these products “in terms of quality and effectiveness”. At the moment, Cavaleri recalled, “we are evaluating the authorization application for the” immunosuppressant “baricitinib and 4 monoclonal antibodies or combinations of antibodies are under rolling review”.